Expectations were already high heading into Mesoblast Ltd (ASX: MSB) latest quarterly update.
The biotech delivered another milestone-filled quarter, with rising revenues and continued progress toward commercialisation in the United States.
Yet instead of pushing higher, Mesoblast shares have slipped 3.33% to $2.61 as the market digested the numbers.
Today's reaction appears investors are looking for more than just the company's progress alone.
Here's what was reported.
Image source: Getty Images
Revenue lifts as Ryoncil rollout continues
According to the release, Mesoblast reported net revenues of US$30 million for the quarter, driven by continued uptake of Ryoncil in the United States.
Gross sales reached US$35 million for the quarter. Demand continues to build following FDA approval for use in children with steroid-refractory acute graft-versus-host disease.
In addition, more treatment centres are coming online. Mesoblast also pointed to steady progress in real-world use, with early post-approval data showing survival outcomes broadly consistent with clinical trial results.
The group continues to work with hospitals and payers to support broader adoption, as awareness of the therapy increases across specialist treatment centres.
Cash burn remains the key focus
While revenue growth is encouraging, the quarterly cash flow statement explains the share price reaction.
Mesoblast recorded net operating cash outflows of US$15.6 million for the quarter. Research and development spending remained high, while manufacturing and operating costs also continued as the company supports commercial scale-up.
At quarter end, Mesoblast held US$130 million in cash and cash equivalents. That gives it around 11.6 quarters of funding based on current burn rates, which provides breathing room but not financial flexibility.
The company also drew down US$75 million from a new US$125 million credit facility during the quarter. While this strengthens short-term liquidity, debt funding always raises investor concerns around future dilution or refinancing risk.
Progress on pipeline beyond Ryoncil
Beyond its approved product, Mesoblast continues to advance several late-stage programs.
The confirmatory Phase 3 trial for chronic low back pain remains active across multiple US sites. The company also highlighted regulatory engagement with the FDA around a potential biologics licence application for heart failure, which could become a meaningful driver if timelines stay on track.
Foolish takeaway
Mesoblast's latest update shows a business that is transitioning out of its development phase and into commercial execution.
From here, the biotech's shares are likely to be judged quarter by quarter on revenue growth, costs, and how quickly the company can reduce its cash burn.
That means the market will start looking at progress to show up in the financials. Until it does, short-term share price swings are likely to continue.
